Naffouje Samer A, Tulla Kiara A, Khalaf Zaynab, Salti George I
Department of General Surgery, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA.
College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
J Gastrointest Oncol. 2019 Apr;10(2):194-202. doi: 10.21037/jgo.2018.12.05.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are increasingly being offered to patients with peritoneal carcinomatosis (PC). On the other hand, the prevalence of obesity is also increasing and expected to reach unprecedented rates in the upcoming decades. Therefore, managing patients on either extreme of the body mass index (BMI) range is anticipated to become a routine challenge and it becomes imperative to understand the impact of BMI, as a spectrum, on the long-term outcomes of CRS and HIPEC. We aim to study the short and long-term outcomes of CRS and HIPEC in patients on both extremes of the BMI spectrum.
Patients with PC who underwent CRS and HIPEC over 10 years for ovarian, colorectal, and pseudomyxoma peritonei (PMP), and whose BMI was recorded were retrospectively included. Patients were divided based on their weight strata. The primary outcomes were disease-free survival (DFS) and overall survival (OS).
A total of 126 patients were included. Fifty-seven point one percent were females and mean age was 59.31±1.57 years. No difference was noted between the groups in regards to demographics, perioperative characteristics, and immediate postoperative outcomes. Underweight group had a trend toward a higher peritoneal cancer index and lower rates of complete cytoreduction. Optimum BMI for OS and DFS was in the obesity range in colorectal PC, in the overweight range in ovarian PC, and in borderline obesity in PMP. Regression analysis identified underweight as an independent risk factor for shorter DFS, whereas underweight and morbid obesity were risk factors for shorter OS, after adjustment for other factors such as incomplete cytoreduction, tumor histology, and grade.
OS and DFS vary across the BMI strata. Ovarian PC demonstrates earlier recurrence and shorter survival, whereas colorectal PC demonstrates the "obesity paradox" as patients move into the realm of obesity. BMI extremes, low or high, generally carry a poor prognosis for OS.
细胞减灭术(CRS)和腹腔热灌注化疗(HIPEC)越来越多地应用于腹膜癌(PC)患者。另一方面,肥胖的患病率也在上升,预计在未来几十年将达到前所未有的水平。因此,管理体重指数(BMI)范围两端的患者预计将成为一项常规挑战,了解BMI作为一个连续变量对CRS和HIPEC长期疗效的影响变得至关重要。我们旨在研究BMI范围两端的患者接受CRS和HIPEC的短期和长期疗效。
回顾性纳入10年间接受CRS和HIPEC治疗的卵巢癌、结直肠癌和腹膜假黏液瘤(PMP)患者,记录其BMI。根据体重分层对患者进行分组。主要结局为无病生存期(DFS)和总生存期(OS)。
共纳入126例患者。57.1%为女性,平均年龄为59.31±1.57岁。两组在人口统计学、围手术期特征和术后即刻结局方面无差异。体重过轻组的腹膜癌指数有升高趋势,完全细胞减灭率较低。结直肠癌患者OS和DFS的最佳BMI范围为肥胖,卵巢癌患者为超重,PMP患者为边缘性肥胖。回归分析确定,在调整了不完全细胞减灭、肿瘤组织学和分级等其他因素后,体重过轻是DFS缩短的独立危险因素,而体重过轻和病态肥胖是OS缩短的危险因素。
OS和DFS在不同BMI分层中有所不同。卵巢癌患者复发较早,生存期较短,而结直肠癌患者随着进入肥胖范围出现“肥胖悖论”。BMI过高或过低通常提示OS预后较差。